Botulinum Toxin Administration for Hemifacial Spasm
For hemifacial spasm, inject botulinum toxin type A primarily into the periocular muscles (orbicularis oculi) at standardized sites, with selective lower facial muscle injections only when clinically indicated by spasm severity in those regions.
Primary Injection Technique
The standard approach targets the orbicularis oculi muscle at 3 standardized periocular sites on the affected side 1, 2. This isolated periocular injection technique has been demonstrated to provide comparable efficacy to more extensive injection patterns while minimizing adverse effects and using lower total toxin doses 3.
Key Technical Points:
- Pretarsal injection is superior to preseptal injection, with patients reporting 75% improvement versus 72.7% improvement respectively 1
- Average dose: 34.5 units per treatment session 1
- Onset of improvement: approximately 8 days 1
- Duration of effect: 14.8 weeks on average 1
Lower Facial Muscle Considerations
Add lower facial injections (zygomatic major/minor, orbicularis oris) only when:
- Spasms clinically involve the mid and lower face regions
- Periocular-only treatment leaves residual lower facial symptoms
- Patient specifically requests treatment of lower facial spasms
The isolated periocular approach demonstrated non-inferiority to conventional periocular plus lower face injections, with mean differences in visual analog scale scores not exceeding the non-inferiority margin 3. Lower facial injections increase the risk of mouth drooping, which occurred only with conventional (combined) injections 3.
Concentration Selection
Two concentration options are clinically effective:
- High concentration (50 U/mL): Longer duration of efficacy but more pronounced adverse reactions
- Low concentration (25 U/mL): Similar onset time and therapeutic efficacy with milder, shorter-duration adverse reactions 4
Select concentration based on patient tolerance for adverse effects versus desire for prolonged symptom control. Both concentrations show equivalent onset time and overall therapeutic efficacy 4.
Contralateral Injection Strategy
Consider contralateral injections (10-15 IU over zygomatic major/minor muscles) specifically for:
- Facial asymmetry in resting position after initial treatment
- Asymmetry during dynamic facial movements
- Patient dissatisfaction with cosmetic appearance 5
This approach improves facial symmetry and is desired by most patients (5 of 6 in reported series) for subsequent treatments 5. However, be aware that long-term unilateral treatment may induce contralateral neuromuscular transmission abnormalities, with electrophysiological evidence showing 21.1% decrease in contralateral CMAP amplitudes and increased jitter values 6.
Critical Safety Considerations
Botulinum toxin does NOT diffuse to non-injected muscles at clinically effective doses when proper technique is used. Studies demonstrate no clinical weakness or CMAP amplitude reduction in untreated orbicularis oris or contralateral facial muscles 2. This supports precise, targeted injection rather than diffuse administration.
Common Adverse Effects (in order of frequency):
- No adverse effect: 79.7% of injections
- Erythema/ecchymosis/swelling: 4.9%
- Facial asymmetry: 3.6%
- Ptosis: 3.4%
- Diplopia: 3.2%
- Difficulty with eye closure: 2.3% 1
All adverse reactions resolve spontaneously without specific treatment in relatively short timeframes 4.
Formulation Equivalence
Botox and Dysport demonstrate similar efficacy and side effect profiles for hemifacial spasm treatment 1. Choose based on availability and institutional preference rather than perceived superiority of one formulation.
Clinical Outcomes Beyond Spasm Control
BTX-A treatment significantly improves psychological health parameters including somatization, tension, anxiety, depression, and sensitivity scores at 2 months post-treatment 7. The total effective rate (complete + significant + partial relief) reaches 89.2%, with 64.6% achieving complete relief 7. This dual benefit—neurological symptom control plus mental health improvement—reinforces BTX-A as first-line therapy 8, 7.